natgillin/translations-raw huggingface dataset:
The residue was purified by flash chromatography (SiO2) using 35% ethyl acetate-hexanes to give the desired product (2.53 g) as an off-white solid. 
Ostatak se pročisti svjetlosnom kromatografijom (SiO,) uporabom 35% etil acetat-heksana da bi se dobio željeni produkt (2.53 g) kao bijela krutina.
The mixtures according to the invention were applied pre- or post-emergence (foliar treatment). 
Smjese prema izumu su primjenjivane prije ili poslije nicanja (folijarni tretman).
A composition comprising about 2 mg to about 25 mg of buprenorphine and a therapeutically effective amount of Compound-1, wherein Compound-1 has the structure: 
Pripravak koji sadrži 1:1 maseni omjer buprenorfina prema Spoju- 1, pri čemu Spoj- 1 ima strukturu:
An isolated mutant staphylococcal leukocidin subunit polypeptide comprising a wild-type staphylococcal leukocidin subunit except for one to five amino acid substitutions at conserved residues, which reduce toxicity of the mutant leukocidin subunit relative to the corresponding wild-type leukocidin subunit; wherein the wild-type leukocidin subunit comprises the amino acid sequence SEQ ID NO: 6 and wherein the mutant staphylococcal leukocidin subunit polypeptide comprises an amino acid substitution at a position corresponding to K97 of SEQ ID NO: 6, 
Izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 5, 6 ili 15, naznačen time što mutant polipeptida stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K97 u SEQ ID NO: 6 što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina;
The communication method according to one of claims 6-8, wherein the second search space is configured on a resource which does not overlap with the first search space within the one PRB set. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 do 10, naznačen time što se drugi prostor za pretraživanje konfigurira na resursu koji se ne preklapa s prvim prostorom za pretraživanjem unutar jednog PRB skupa.
The method of clause 22, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da jest za uporabu u smanjivanju učestalosti relapsa kod pacijenta koji pati od relapsno remitirajuće multiple skleroze.
In another most preferred embodiment, the system for cell cultivation comprises a bioreactor comprising an internal column, wherein the solid support for cultivation of anchorage-dependent cells is located within said internal column. 
U drugoj poželjnoj izvedbi, sustav za stanični uzgoj obuhvaća bioreaktora s unutarnjom kolonom, gdje se kruta potpora za uzgoj stanica koje potrebuju pričvršćivanje nalazi u spomenutoj koloni.
A process for the preparation of a compound of formula (3): 
Postupak za dobivanje spoja formule (5): koji obuhvaća kupliranje spoja formule (3):
A method according to claim 2 wherein the metal is an alkali or alkali earth metal. 
Postupak sukladno zahtjevu 10, naznačeno time, da je metal alkalni metal.
In another embodiment the invention is a compound according to any of statements 1 to 5 for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine i metastaze.
In certain embodiments, the alkylating agent and anti-CD20 agents are administered one or more times prior to administration of the PNP inhibitor. 
Forodesin u kombinaciji s rituksimabom, namijenjeni upotrebi u skladu s patentnim zahtjevom 9, naznačeni time što se alkilirajuće sredstvo primijenjuje jedan ili više puta prije primjene forodesina.
As previously indicated, instead of system 10 being stationary relative to moving agricultural crop, system 10 could be moved past stationary agricultural crop. 
Kao što je ranije ukazano, umjesto da sustav 10 bude nepokretan u odnosu na pokretni poljoprivredni usjev, sustav 10 se može pomicati duž nepokretnog poljoprivrednog usjeva.
The use of the vesicles of any of claims 1-6, in the manufacture of a cosmetic product, preferably wherein the cosmetic product is a product to prevent senescence and aging of the skin. 
Upotreba čestica iz bilo kojeg od patentnih zahtjeva 1-6, u proizvodnji kozmetičkog proizvoda, preporučljivo da je kozmetički proizvod proizvod za sprječavanje propadanja kao u slučaju starosti i starenja kože.
controlling (106, 2010, 2012) the movement of said stabilizing fin as a function of said path. 
- < kontroliranje (106, 2010, 2012) kretanja navedene stabilizirajuće peraje kao funkcije navedene putanje.
The method of claim 12, wherein the condition is selected from the group consisting of esophageal squamous cell carcinoma, gastric cancer, glioblastomas, astrocytomas, retinoblastoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rabdomysarcoma, Wilm's tumor, basal cell carcinoma, non-small cell lung cancer, brain tumour, hormone refractory prostate cancer, prostate cancer, metastatic breast cancer, breast cancer, metastatic pancreatic cancer, pancreatic cancer, colorectal cancer, cervical cancer, head and neck squamous cell carcinoma, and cancer of the head and neck. 
Spoj iz zahtjeva 15, naznačen time da je stanje odabrano: karcinoma pločastih stanica jednjaka, raka želuca, glioblastoma, astrocitoma; retinoblastoma, osteosarkoma, hondosarkoma, Ewingova sarkoma, rabdomisarkoma, Wilmova tumora, bazalnocelularnog karcinoma, ne-sitnostaničnog raka pluća, tumora mozga, refraktornog hormonalnog raka prostate, raka prostate, metastatskog karcinoma dojke, raka dojke, metastatskog karcinoma gušterače, raka gušterače, kolorektalnog karcinoma, raka grlića maternice, karcinoma pločastih stanica glave i vrata i raka glave i vrata.
A method of supplying fuel gas to a high-pressure gas injection engine of a vessel in which an LNG tank is provided, comprising: compressing LNG to meet the pressure requirements of the high-pressure gas injection engine; and 
Postupak dobave pogonskog plina u visokotlačni plinski injekcijski motor plovila osim za LNG tanker u kojem je predviđen spremnik LNG (1), koji sadrži: komprimiranje LNG pomoću prve crpke (2), i dobavu stlačenog LNG prema drugoj crpki (4) koja dodatno komprimira LNG kako bi se udovoljilo zahtjevima tlaka za visokotlačni plinski injekcijski motor, te zatim uplinjavanje LNG;
A hand held medicine dosing and dispensing device according to Claim 13, wherein the drive motor forms part of the ejection mechanism and is controllable to drive the feed wheel to rotate in a second direction to disengage the latch members and allow removal of the cassette from the housing. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevu 13, naznačen time da pogonski motor tvori dio mehanizma za izbacivanje kojim je moguće upravljati radi pokretanja dobavnog kotačića da rotira u drugom smjeru radi oslobađanja elemenata zasuna, te da se omogući uklanjanje kasete iz kućišta.
An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of the protein scaffold of any one of claims 1-4, optionally wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system. 
Segment proizvodnje za humanu farmaceutsku ili dijagnostičku upotrebu, sadrži pakiranje materijala i spremnik koji sadrži otapalo ili liofilizirani oblik platformskog proteina prema bilo kojem od patentnih zahtjeva od 1 do 4, pri čemu je, opcionalno, spomenuti spremnik sastavni dio uređaja ili sustava za isporuku koja je parenteralna, potkožna, intramuskularna, intravenozna, intraartikularna, intrabronhijalna, intraabdomenalna, intrakapsularna, intrakartilaginozna, intrakavitarna, intracelijalna, intracerebralna, intracelebroventikularna, intrakolična, intracervikalna, intragastrična, intrahepatička, intramiokardialna, intraostealna, intrapelvična, intraperikardialna, intraperitonealna, intrapleuralna, intraprostatična, intrpulmonarna, intrarektalna, intrarenalna, intraretinalna, intraspinalna, intrasinovijalna, intratorakična, intrauterusna, intravezikalna, intralezionalna, individualna, vaginalna, rektalna, bukalna, podjezična, intranazalna, ili transdermalna.
the sequential reaction of compounds of the Formula II 
Datum podnošenja europske prijave patenta:
3, 4 and 5 a lower capsule detaching unit (capsule ejector) 20 is shown. 
Na slikama 3, 41 5 je prikazana donja jedinica za odvajanje čahure (naprava za izbacivanje čahure) 20.
The latter may be converted to (7a)-3-methoxy-7-methyl-D-homoestra-1,3,5(10)-trien-17a-one by e.g. catalytic hydrogenation. 
Potonjeg se, primjerice katalitičkom hidrogenacijom, može prevesti u (7a)-3-metoksi-7-metil-D-homoestra-1,3,5(10)-trien-17a-on.
a liquid cosmetic, wherein the hard vegetable butter is a high saturated vegetable butter having greater than 60 wt% saturated fatty acids based on total fatty acid content of the high saturated vegetable butter, wherein the soft vegetable butter is a low saturated vegetable butter having less than 60 wt% saturated fatty acids based on total fatty acid content of the low saturated vegetable butter, and wherein "solid" means that the cosmetic composition can substantially sustain its physical shape when unsupported by external means, and wherein the solid cosmetic composition is solid at room temperature and remains substantially solid at up to a temperature of 30°C. 
(c) tekući kozmetički proizvod, pri čemu je tvrdi biljmi maslac visoko zasićeni biljni maslac koji ima više od 60 mas.% zasićenih masnih kiselina temelju ukupnog sadržaja masnih kiselina visoko zasićenog biljnog maslaca, pri čemu je mekani biljni maslac nisko zasićeni biljni maslac koji ima manje od 60 mas.% zasićenih masnih kiselina temelju ukupnog sadržaja masnih kiselina nisko zasićenog biljnog maslaca, i pri čemu "kruti" znači da kozmetički pripravak može uglavnom zadržavati svoj fizički oblik kada nije podržan vanjskim sredstvima, te pri čemu kruti kozmetički pripravak je krut na sobnoj temperaturi i ostaje uglavnom krut na temperaturi do 30?C.
A most useful application is found in the treatment of infantile hemangiomas. 
Otopina sukladno patentnom zahtjevu 1, za uporabu kao lijek u liječenju kapilarnih dječjih hemangioma.
The process according to claim 1 or 2, wherein the B-(substituted-amino)acid ester comprises a carboxylic acid ester portion R14-O-C(O)-, wherein R14 is alkyl or aryl. 
Postupak prema patentnom zahtjevu 1 ili 2, gdje B-(supstituirani-amino)kiselinski ester obuhvaća udio estera karboksilne kiseline R14-O-C(O)-, pri čemu je R14 alkil ili aril.
The reaction mixture was then diluted with water (100 ml.) 
Reakcijska smjesa se tada razblaži s vodom (100 ml.)
288,732 during the extrusion-spheroidization process organic acids (such as citric, tartaric, maleic, fumaric, succinic acid) applied in the composition in an amount of 5 to 50% by weight improve the plasticity of the wet mass and thus enable the preparation of harder pellets with particles of a narrow size range. 
288,732 ako se tijekom procesa ekstruzije-sferoidizacije u smjesu dodaju organske kiseline (kao što su limunska, vinska, maleinska, fumarna, jantarna kiselina) u količini od 5 do 50% (težinski) poboljšava se plastičnost vlažne mase i time omogućuje priređivanje tvrđih tableta s česticama koje su užeg veličinskog raspona.
The process according to claim 10, in which said carbonaceous inducer substrate in phase a′) is identical to the carbonaceous inducer substrate in the production phase b). 
Postupak prema zahtjevu 9, naznačen time da je navedeni karbonatni inducirajući supstrat koji je korišten u fazi a) identičan karbonatnom inducirajućem supstratu korištenom u fazi proizvodnje b).
adding the antibody according to any one of claims 1-14 to a biological sample comprising or suspected of comprising AB protofibrils. 
- < dodavanje protutijela prema bilo kojem od zahtjeva 1-14 biološkom uzorku koji sadrži ili je suspektan na sadržaj AP protofibrile.
The compound according to claim 1 wherein R2 is a group (b). 
Spoj prema zahtjevu 1, naznačen time, da R? je skupina (b).
While the same anisaldehyde group is used at both the 7,9-acetal and N,O-acetal in the exemplary compound of Formula 29, such that both groups may be removed in a single step, it should be appreciated that other acetal protecting groups are contemplated such that multiple deprotection steps may be required. 
Dok se ista anisaldehid skupina koristi i za 7,9-acetal 1 N,O-acetal u spoju formule 29 koji je uzet kao primjer, tako da obje skupine mogu biti uklonjene u samo jednom koraku, trebalo bi uvažiti da se 1 druge acetal zaštitne skupine razmatraju na takav način da se mogu zahtijevati mnogostruki koraci za uklanjanje zaštite.
The invention provides a dry powder formulation comprising a compound (I), a carrier such as lactose and a ternary agent which is magnesium stearate, for use in the treatment of respiratory diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD) wherein Compound (I) is administered by inhalation at a dose of 12.5, 25 or 50 µg per day, calculated as the free base. 
OH CI Spoj (I) ili njegove farmaceutski prihvatljive soli, u obliku suhog praha, nosač i ternarno sredstvo, gdje je ternarno sredstvo magnezijev stearat, te gdje se Spoj (I) primjenjuje inhalacijom u dozi od 12,5, 25 ili 50 ug dnevno, izračunatoj kao slobodna baza namijenjena upotrebi u liječenju bolesti dišnog sustava.
The antibody of claim 1, wherein the antibody exhibits greater than 50% inhibition of Mac-1 binding to the fibrin or fibrinogen YC domain. 
Protutijelo iz patentnog zahtjeva 1, pri čemu protutijelo pokazuje više od 20% inhibicije vezanja Mac-I za yC domenu fibrina ili fibrinogena.
The composition for use of claim 8, wherein the compounds are linked with a cleavable or non-cleavable linker. 
Smjesa za uporabu prema zahtjevu 8, gdje su spojevi povezani linkerom koji se može ili ne može razgraditi.
A process according to claim 1, wherein the equivalent ratio of 3-phenoxypropyl bromide to 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl ester is in the range from 1.0 to 3.0. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je odgovarajući omjer 3-fenoksipropil bromida do 2-hidroksi-2,2-ditien-2-iloctena kiselina 1-azabiciklo[2.2.2]okt-3(R)il estera u rasponu od 1.0 do 3.0.
A compound of formula (1) or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a central nervous system disorder wherein the central nervous system disorder is selected from the group consisting of Friedreich's ataxia, a brain injury, a rare metabolic disease, global or local ischemia, intracerebral haemorrhage, stroke, vascular dementia, meningitis, encephalitis, rabies, measles, mumps, poliomyelitis, herpes simplex, varicella zoster, and a metastasis of a primary brain tumor. 
Spoj formule (1), ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju poremećaja središnjeg živčanog sustava, gdje se poremećaj središnjeg živčanog sustava bira iz skupine koju čine neurodegenerativne bolesti, cerebrovaskularne bolesti, napadaji, epilepsija, virusne bolesti, neuroupalne bolesti, tumori na mozgu, organske acidemije, poremećaji masnih kiselina i genetički mitohondrijski poremećaji.
A mouse having a genome comprising a modification of an immunoglobulin heavy chain locus, wherein the modification eliminates endogenous ADAM6 function, which is associated with a reduction in fertility in male mice, the mouse further comprising nucleic acid sequences encoding a mouse ADAM6a protein, or an ortholog or homolog or functional fragment thereof that is functional in a male mouse, and a mouse ADAM6b protein, or an ortholog or homolog or fragment thereof that is functional in a male mouse. 
ektopičnu sekvencu nukleinske kiseline koja sadržava sekvencu koja kodira mišji protein ADAM6a ili njegov ortolog ili njegov homolog ili njegov fragment koji je funkcionalan u muškom mišu, i mišji protein ADAM6b ili njegov ortolog, ili njegov homolog ili njegov fragment koji je funkcionalan u muškom mišu, pri čemu su mišji protein ADAM6a ili njegov ortolog ili njegov homolog ili njegov fragment i mišji ADAM6b protein ili njegov ortolog ili njegov homolog ili njegov fragment eksprimirani iz ektopične sekvence nukleinske kiseline; i
The amount of azelastine in such compositions suitably is about 0.05% to about 0.15% by weight, and the amount of sucralose in such compositions is suitably about 0.05% to about 0.15% by weight. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni azelastin prisutan u navedenom pripravku u koncentraciji od 0,15%, težinski, a navedena sukraloza je prisutna u navedenom pripravku u koncentraciji od 0,15%, težinski.
A human engineered DKK-1 antibody or antigen-binding fragment thereof, for use according to claim 1 wherein the cancer is selected from multiple myeloma, breast cancer, and non-small cell lung cancer. 
Ljudsko konstruirano protutijelo protiv DKK-I1, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se rak bira između multiplog mijeloma, raka dojke, te raka velikih stanica pluća.
13-22E shows pictures of the packaging, 
prikazuje stanje tehnike pakiranja, i
A represents a tetrazoyl group of formula (A1) or (A2): 
* A predstavlja skupinu tetrazoil s formulom (A'): i
Additionally, the consumption of draught beer is very sensitive to seasonal variation. 
K tome, potrošnja piva iz bačve je vrlo osjetljiva na promjene sezona.
A process for producing a pharmaceutical composition according to claim 2 or a nutritional supplement according to claim 3, said process comprising admixing the bacterial strain with a pharmaceutically acceptable excipient, carrier or diluent or a nutritionally acceptable excipient, carrier or diluent. 
Postupak za proizvodnju farmaceutskog sastava prema zahtjevu 2, naznačen time što sadrži miješanje bakterijske vrste Roseburia hominis sa farmaceutski prihvatljivim ekscipijensom, nosačem ili diluentom.
A prolonged release mucoadhesive buccal tablet according to claim 4 for use according to claim 4 wherein the at least acyclic guanosine antiviral agent is in an amount of 50 mg. 
Mukoadhezivna bukalna tableta s produljenim otpuštanjem u skladu s patentnim zahtjevom 4, namijenjena upotrebi u skladu s patentnim zahtjevom 4, naznačena time što je u najmanju ruku acikličko gvanozinsko protuvirusno sredstvo prisutno u količini od 50 mg.
The immunogenic composition of claim 6 wherein Protein E from Haemophilus influenzae and PilA from Haemophilus influenzae are present as a fusion protein. 
Imunogeni pripravak u skladu s patentnim zahtjevom 8-9, naznačen time što dodatno sadrži antigene iz bakterije Haemophilus influenzae Protein E, PilA ili Protein E i PilA kao fuzijski protein.
The process of claim 2, further comprising a step of preparing the compound of formula 4-ii: by reacting a compound of formula 4-i: under suitable chlorooxime formation conditions. 
10 4. - Postupak u skladu s patentnim zahtjevom 2, naznačen time, da nadalje obuhvaća korak pripreme spoja formule 4-ii:
Therefore, it will be appreciated that the voltage at the secondary winding 330 of current transformer 300 is rectified by diodes 310 and 311, thus across resistor 111a a pulsing signal proportional to the current flowing into conductor 14 will be provided. 
Radi toga, bit će pretpostavljeno da je napon na sekundarnom namotu 330 strujnog transformatora 300 ispravljen diodama 310 i 311, i tako daje na otporniku 111a pulsni signal proporcionalan struji koja teče kroz vodič 14.
The present embodiments are, therefore, to be considered in all respects to be illustrative and not restrictive. A communication method comprising: receiving resource assignment information including a plurality of bits that indicate activation or deactivation statuses of respective downlink component carriers, the downlink component carriers being secondary downlink component carriers added to a primary component carrier which is always activated, each of the downlink component carriers corresponding to one bit included in the plurality of bits, and the one bit indicating that a corresponding downlink component carrier is to be activated or deactivated, wherein when any one bit of the plurality of bits indicates that its corresponding downlink component carrier is to be activated, the plurality of bits jointly indicate the activation or deactivation statuses, a sounding reference signal (SRS) transmission request and a channel quality information (CQI) reporting request; 
Komunikacijska metoda sadržeći: prijem informacija o raspoređivanju resursa, uključujući pluralitet bitova koji pokazuju statuse aktivacije ili deaktivacije odgovarajućih nosača komponenti silazne veze, nosači komponenti silazne veze su sekundarni nosači komponenti silazne veze dodani primarnom nosaču komponenti koji je uvijek aktiviran, svaki nosač komponenti silazne veze odgovara jednom bitu koji je uključen u pluralitet bitova, i taj jedan bit pokazuje da li se treba aktivirati ili deaktivirati odgovarajući nosač komponenti silazne veze, naznačeno time da kad bilo koji bit među pluralitetom bitova ukazuje da treba aktivirati odgovarajući sekundarni nosač komponenti, pluralitet bitova dalje označava zahtjev za prijenos sondirajućeg referentnog signala, SRS; aktivaciju ili deaktivaciju svakog od nosača komponenti silazne veze sukladno informacijama o raspoređivanju resursa; i prijenos SRS prijenosa na aktiviranim sekundarnim nosačima komponenti.
a medical composition for the treatment or prophylaxis of glaucoma which comprises a compound represented by the following formula (1) 
Medicinska oftalmološka otopina za uporabu u liječenju ili profilaksi glaukoma koja sadrži spoj piridilaminooctene kiseline predstavljen formulom (1):
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein: 
r: d WII ili njegov enantiomer ili smjesa enantiomera ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, naznačen time, da:
The separation apparatus (2) as claimed in claim 1 or 2, characterised in that the housing (2) includes at least one distribution screen (11) adapted to aid distribution of the fluid flowing through the screen. 
Uređaj za razdvajanje (2) u skladu s patentnim zahtjevom 1, karakteriziran na način da kućište (2) uključuje najmanje jednu pregradu za raspodjelu (11) prilagođenu za pomaganje raspodjele tekućine koja protječe kroz pregradu.
subjecting the second stream to a second separation stage, capable of recovering suspended solids from a liquid, to recover a third stream rich in the protein-containing fermentation agent and a fourth stream comprising dissolved solids, suspended solids, or both in water. 
(iv) podvrgavanje druge struje drugoj fazi odvajanja koja obuhvaća korak centrifugalnog odvajanja, sposobne za ponovno dobivanje suspendirane krute tvari 1z tekućine, da se dobije treća struja bogata s fermentacijskim sredstvom koje obuhvaća topive ne-škrobne polisaharide i četvrta struja bogata s vodenom otopinom; te formuliranje obnovljenog fermentacijskog sredstva kao izvora proteina kao krmiva za uporabu u pripravku hrane za životinje.